NCT Number: NCT05932862
Phase: PHASE1
Trial Summary: This is a first-in-human, multicenter, open-label Phase I study. The study will be comprised of a dose escalation part followed by a dose selection optimization part. – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Exelixis
Acronym:
Study of XL309 (ISM3091) in Patients With Advanced Solid Tumors
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives